- Data analytics provider to the pharmaceutical industry Diaceutics posted a first-half loss after rising revenue was offset by one-off IPO costs.

Pre-tax losses for the six months through June amounted to £1.97m, compared to losses of £1.17m on-year.

Revenue rose 34% to £4.4m, offset by IPO-related costs of £1.4m.

Gross profit rose 71% to £3.1m.

' We decided to move to AIM to continue our growth trajectory by developing our product and services offering which is focused on better testing and better treatment in the global pharmaceutical industry,' chief executive Peter Keeling said.

'We have seen good growth since we came to market and continue to work hard on expanding the data lake and increasing our international footprint. I reaffirm our outlook for the year remains unchanged.'

At 2:12pm: [LON:DXRX] share price was 0p at 92.5p

Story provided by